COVID-19 vaccine CDMO agreement signed

toktok newsletter will keep you up-to-date with the latest news on SK and affiliates.

 

 

 

SK bioscience has signed a CDMO (Contract Development Manufacturing Organization) agreement with the US biotechnology company Novavax specialized in the development of next-generation vaccines to develop and produce antigens for the COVID-19 vaccine candidate NVX-CoV2373 and supply it to the global market including Korea. The CDMO agreement allows Novavax to transfer its antigen manufacturing technologies for its COVID-19 vaccine candidate NVX-CoV2373 currently under development to SK bioscience who will then develop subsequent processes and produce it in its Andong Vaccine Plant L House for global supply. NVX-CoV2373 is now in clinical trial phase 2 and is expected to enter into phase 3 by October at the earliest. According to the clinical trial phase 1 results released by Novavax on August 4, neutralizing antibodies safe and required for immunity were found in all 131 adults to whom NVX-CoV2373 was administered two times, with their antibody concentration significantly higher than that observed in serum samples of recovering COVID-19 patients. As agreed in the contract, SK bioscience, possessing both synthetic antibody technology and cell culture production solution applied to NVX-CoV2373, will start developing NVX-CoV2373 production processes and producing undiluted solution in its Vaccine Plant L House in Andong, Kyeongbuk Province in August.

 

 

 

SK C&C has completed the migration of KEROL-a global integrated logistics system owned by SK telecom’s global logistics arm FSK L&S-to a cloud container service platform. KEROL is a system designed to manage the entire spectrum of logistics services for the global market, ranging from cargo receipt/release/inventory/shipping; and export/import cargo shipping and customs clearance; to interface with air carriers, marine shipping companies, warehouse owners, and inland transportation service providers. SK C&C used Cloud Z CP (Container Platform) on AWS which is the AWS version of cloud container service platform to build the cloud container service for KEROL in just two months. FSK L&S will leverage the migration project as a momentum to incorporate digital innovation technologies in service offerings across KEROL’s logistics service portfolio, adopting AI-enabled structured/non-structured data analysis, standardization based on IoT and blockchain, and streamlined and efficient logistics processes.

 

 

 

Nano-x, a next-generation medical equipment tech-builder preemptively invested by SK telecom, has been successfully listed on NASDAQ on August, 21 local time. The Israeli company is trying to commercialize Nanox.Arc that leverages semiconductor-based digital X-ray technology to deliver greater price competitiveness and performance than conventional X-ray imaging systems. In recognition of its technological excellence, Nano-x has made its way into NASDAQ as an emerging growth company. SK telecom strategically invested a total of USD 23 million in the company in June 2019 and June 2020, actively contributing to the company’s management and global business deployment as the second-largest shareholder only next to its related parties (founder and top management leaders). Core Nano-x semiconductor FAB will be built in Korea and a variety of joint business opportunities leveraging 5G and AI technologies will be explored.